Lung Cancer, Non-Small Cell
133
29
42
33
Key Insights
Highlights
Success Rate
65% trial completion
Published Results
21 trials with published results (16%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
13.5%
18 terminated out of 133 trials
64.7%
-21.8% vs benchmark
8%
10 trials in Phase 3/4
64%
21 of 33 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 33 completed trials
Clinical Trials (133)
Feasibility and Effectiveness of Respiratory Movement Management in Lung Cancer Receiving Stereotactic Radiotherapy Using a Novel Positional Fixation Device
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer
Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients
Sleeve Lobectomy for Lung Cancer in Minimally Invasive Surgical Techniques
ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients
Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
Effectiveness of a Multimodal Outpatient Supervised Physical Activity Program to Improve Tolerance and Efficacy of Chemotherapy in Adults With Breast, Lung and Colon Cancer
Multimodal Nutritional and Sarcopenia Assessment for Risk Stratification in Lung Cancer Surgery
Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib
Immune Response to Immunotherapy in Lung Cancer: Study of Sputum and Blood Samples
IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
Palliative Thoracic ImmunoRT
Prospective Data Collection Initiative on Thoracic Malignancies
Engagement of Veterans With Lung Cancer
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
A Phase II Study of SKB571 in Patients With Lung Cancer
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)